Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70.Why did oncologists give a standing ovation to a data presentation on Revolution Medicines’ pancreatic cancer drug, daraxonrasib? Why did biotech stocks perform so badly this week? And are concrete beaches better than normal beaches?
We discuss all that and more on this week’s episode of “The Readout LOUD,” STAT’s biotech podcast.
We bring on Leanna Stokes, who was diagnosed with metastatic pancreatic cancer in 2023. She discusses how participating in RevMed’s trial for daraxonrasib has affected her disease and life, and what the drug means for patients and the field.
We also chat about other data presented during last week’s meeting of the American Society of Clinical Oncology, the market reaction to Abivax’s ulcerative colitis data, and the upcoming meeting of the American Diabetes Association.
For more on RevMed’s data presented at ACSO, go here; to read more on Leanna’s story, go here. For more on our other ASCO coverage, go here. To read more on Abivax’s readout, go here; and to sign up for our coverage of the ADA meeting, go here.
